| Compound | Indication | Stage | Territory |
 |
|||
| SPK-0601 | Herpes labialis, Herpes genitalis, Herpes zoster, Condyloma |
Pre-clinical | World wide |
|
|
|||
| SPK-0602 | Vulvovaginitis | Phase II (EU) Approved (Switzerland) |
World wide |
|
|
|||
| Compound | Indication | Stage | Territory |
|
|
|||
| SPK-0601 | Herpes labialis, Herpes genitalis, Herpes zoster, Condyloma |
Pre-clinical | World wide |
|
|
|||
| SPK-0602 | Vulvovaginitis | Phase II (EU) Approved (Switzerland) |
World wide |
|
|
|||
| (C) 2008.Copyright Shogoo Pharmaceuticals, AG All rights reserved. |